US20130203157A1 - Microfluidic device for counting biological particles - Google Patents
Microfluidic device for counting biological particles Download PDFInfo
- Publication number
- US20130203157A1 US20130203157A1 US13/830,605 US201313830605A US2013203157A1 US 20130203157 A1 US20130203157 A1 US 20130203157A1 US 201313830605 A US201313830605 A US 201313830605A US 2013203157 A1 US2013203157 A1 US 2013203157A1
- Authority
- US
- United States
- Prior art keywords
- controller
- pump
- sample chamber
- sample
- cell count
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002245 particle Substances 0.000 title claims abstract description 22
- 210000004369 blood Anatomy 0.000 claims abstract description 14
- 239000008280 blood Substances 0.000 claims abstract description 14
- 239000011324 bead Substances 0.000 claims description 55
- 239000012530 fluid Substances 0.000 claims description 44
- 239000011521 glass Substances 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 230000003416 augmentation Effects 0.000 claims description 12
- 210000004970 cd4 cell Anatomy 0.000 claims description 8
- 239000000306 component Substances 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 5
- 238000003384 imaging method Methods 0.000 claims description 5
- 238000005086 pumping Methods 0.000 claims description 4
- 239000012503 blood component Substances 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 63
- 210000004027 cell Anatomy 0.000 description 27
- 238000000034 method Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- -1 washes Substances 0.000 description 3
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 241000283707 Capra Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/06—Investigating concentration of particle suspensions
- G01N15/0606—Investigating concentration of particle suspensions by collecting particles on a support
- G01N15/0612—Optical scan of the deposits
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
- G01N15/1484—Electro-optical investigation, e.g. flow cytometers microstructural devices
-
- G01N2015/016—
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/2575—Volumetric liquid transfer
Abstract
A particle counter for analyzing blood has features which provide for automatic operation and preferably, also provide for portable use in a low resource setting. In a preferred embodiment, preferred embodiment, the device is used to obtain CD4 counts for AIDS diagnosis.
Description
- The present application claims priority to U.S. Provisional Applications 60/947,384 and 60/947,345, filed 29 Jun. 2007 entitled “Microfluidic Device for Counting Cells” hereby incorporated by reference in their entireties herein.
- Practical HIV diagnostics are urgently needed in resource-limited settings. While HIV infection can be diagnosed using simple, rapid, lateral flow immunoassays, HIV disease staging and treatment monitoring require accurate counting of a particular white blood cell subset, the CD4(+) T lymphocyte.
- Current systems for providing this function are expensive, technically demanding and/or time-consuming. For example, CD4 counts may be obtained by conventional flow cytometry. The method requires a slow flow rate to capture the cells on the surface of the channel, followed by a quick wash. This is not easy to implement in a point-of-care device, where the fluid actuation technique must be fairly simple. They require a microscope and a camera (or a person) to count the captured cells. This method is suitable for a lab environment, not point of care.
- According to an embodiment, the invention is a portable microfluidic device for counting CD4+ T-cells. In a method embodiment, the device is used to count CD4+ T-cells and the information from the counting is used as a key diagnostic criterion for determining whether to administer antiretroviral therapy to HIV-infected patients. In the device embodiment, a disposable microfluidic cassette contains densely packed beads for capturing T-cells. A portable, self-powered instrument operatively associated with the microfluidic cassette reads and displays the result of the counting. Preferably, the device employs bead-based microfluidics to enhance surface area for cell capture. For example, in an embodiment, a “double-dam” design is employed which is compatible with whole blood. Preferably, a small pump is employed to permit complete compactness and low power requirement. Also, preferably, the device uses a portable detection device based on an absorbance/chemiluminescence reader. In a particularly preferred embodiment, the detector is powered by a solar batter, which can, for example facilitate its use in point-of-care settings in the developed countries, as well as developing countries.
- In a particular variation, the device uses cell affinity chromatography operated under differential shear flow to specifically isolate CD4(+) T lymphocytes. In an embodiment, the device may be effective with a direct processing of 10 microliters of unprocessed, unlabeled whole blood. CD4 counts are, in this embodiment, obtained under an optical microscope in a rapid, simple and label-free fashion. For example, the embodiments are effective for a range of absolute CD4 counts (R(2)=0.93) over which the embodiments are operable. This CD4 counting microdevice can be used for simple, rapid and affordable CD4 counting in point-ofcare and resource-limited settings.
- In a preferred configuration, packed beads are provided in a microchannel to enhance capture surface area which increases the cell-capture efficiency to enhance the final signal, and allows constant flow, permitting the use of a small pump, preferably peristaltic and preferably powered by a battery. Preferably, capture and detection are done in the same location. Optics are employed that automatically reads the signal either by absorbance or chemiluminescence or some other suitable technique. The optical components are preferably portable and as such, are, in the preferred embodiment, powered by battery including the detection portion, the pumping portion, and the microfluidic channel chip. Preferably, rechargeable batteries are used.
- A portable blood component analysis device has a microfluidic unit with a sample chamber defined in a first longitudinal channel having a first major axis and a second longitudinal channel, having a second major axis, in communication with the first longitudinal channel with the second major axis crossing the first major axis; the sample chamber having a surface augmentation features with biospecific surface configured to capture particles from blood; an analyzer component having a signal detector and a receiving slot configured to receive the microfluidic unit and align the sample chamber with the signal detector. Preferably, the first and second major are substantially perpendicular. Preferably, the analyzer contains a pump configured to generate a vacuum of at least 10 kPa. Preferably, the surface augmentation features include a packed bead bed with glass beads. Preferably, the surface augmentation features include a packed bead bed with glass beads with a diameter between 50 and 100 μm and the first longitudinal channel contains a narrow portion with a minimum dimension of less than the diameter of the glass beads. Preferably, the device further includes a pump, a controller and a solar power source connected to power the pump and controller. Preferably, the microfluidic unit includes a tube containing at least one, at least one wash, and at least one air bubble, the tube being reversibly sealed at both ends and configured to connect with the second longitudinal channel. Preferably, the device further includes a pump, a controller and a solar power source connected to power the pump and controller, wherein the microfluidic unit includes a tube containing at least one, at least one wash, and at least one air bubble, the tube being reversibly sealed at both ends and configured to connect with the second longitudinal channel and wherein the controller is configured automatically to pump fluids from the tube through the sample chamber and through the second longitudinal channel. In any of these devices, the blood particles detected may include CD4 cells. Preferably, a battery is included. Preferably, a controller receives a signal from the signal detector and the signal is a light intensity, the controller being configured to derive a cell count from a light intensity signal without imaging. Preferably, the controller is configured to derive the cell count from a calibration lookup table correlating cell count against total light intensity from the sample chamber.
- Another portable blood component analysis device has a microfluidic unit with a sample chamber; the sample chamber having a surface augmentation features with biospecific surface configured to capture particles from blood. an analyzer component having a signal detector and a receiving slot configured to receive the microfluidic unit and align the sample chamber with the signal detector; Preferably, the surface augmentation features include a packed bead bed with glass beads. The device claim 13, wherein the analyzer contains a pump configured to generate a vacuum of at least 10 kPa; Preferably, the surface augmentation features include a packed bead bed with glass beads with a diameter between 50 and 100 μm and the first longitudinal channel contains a narrow portion with a minimum dimension of less than the diameter of the glass beads. Preferably, the device includes a controller and a solar power source connected to power the pump and controller. Preferably, the microfluidic unit includes a tube containing at least one, at least one wash, and at least one air bubble, the tube being reversibly sealed at both ends and configured to connect with the second longitudinal channel. Preferably, the device has a pump, a controller and a solar power source connected to power the pump and controller, wherein the microfluidic unit includes a tube containing at least one, at least one wash, and at least one air bubble, the tube being reversibly sealed at both ends and configured to connect with the second longitudinal channel and wherein the controller is configured automatically to pump fluids from the tube through the sample chamber and through the second longitudinal channel. Preferably, the blood particles include CD4 cells. Preferably, the device has a battery powered by solar power source. Preferably, the device has a controller and the signal detector is a light intensity detector and the controller is configured to derive a cell count from a light intensity signal without imaging. Preferably, the controller is configured to derive the cell count from a calibration lookup table correlating cell count against total light intensity from the sample chamber. Preferably, the device has a display configured to output a cell count. Preferably, the device has a controller and the signal detector is a light intensity detector and the controller is configured to derive a cell count from a light intensity signal without imaging. The device of claim 23, wherein the controller is configured to derive the cell count from a calibration lookup table correlating cell count against total light intensity from the sample chamber. Preferably, the device includes a pump, a controller and a solar power source connected to power the pump and controller, wherein the microfluidic unit includes a tube containing at least one, at least one wash, and an a chemiluminscence activator, the tube being reversibly sealed at both ends and configured to connect with the second longitudinal channel and wherein the controller is configured automatically to pump fluids from the tube through the sample chamber and through the second longitudinal channel. Preferably, the pump is controlled to vary a pumping rate depending on a sample or reagent passing through the sample chamber.
-
FIG. 1 shows a first embodiment of a sample analyzer. -
FIGS. 2A and 2B show a second embodiment of a sample analyzer. -
FIG. 3 shows a multiple-chamber sample analyzer showing various features. -
FIGS. 4A , 4B, and 4C illustrate embodiments of portable sample analyzer machines. - Referring to
FIG. 1 , a T-shapedmicrofluidic device 100 has asample channel 100S for sample fluid and reagents and aloading channel 100L for loading particles that providing surface augmentation, such as glass orpolystyrene beads 106. The particles preferably carry immobilized biospecific molecules or other reactive substances on their surfaces. Aninlet channel 101 and anoutlet channel 102 are used to convey a sample fluid, such as blood, and reagents and washes through thesample channel 100S. Theloading channel 100L is used to fill achamber 104 with the surface augmentation particles to form a packed bed within thechamber 104. Thebeads 106 are trapped in a cage made up ofmicroposts 108 defining sample inlet,sample outlet fences loading port 107 along with the fluid suspending them into thechamber 104 while permitting the fluid to drain through gaps between theposts 108. The beads may be loaded in by flowing them in a suspension by pumping a fluid into thebed 104 area and drawing excess carrying fluid out through afence 114 trapping thebeads 106 in the bed 105 and packing them with a repeatable density. - Preferably, the gap between the posts is smaller than the breads. The
Posts 108 can be many times the size of the beads. The beads do not have to be a constant size, but preferably they are a consistent size to help ensure a packing arrangement with a large and predictable void volume. If desired, a step may be added, for example, to coat the bead particles with a stabilizing or protecting material. - Although not shown in the drawing, the
chamber 104 is enclosed at the top and bottom. The entire structure can be made using lithographic techniques that are well known. Once packed with the surface augmenting particles,loading channel 100L can be permanently sealed at both ends and the sample channel 1005 temporarily sealed for storage and/or shipping. Thedevice 100 may be combined with multiplesuch devices 100 on a single piece of substrate, each with a bed having a different immobilized biospecific substances to permit detection of different sample fluid components. In use, thesample channel 100L is unsealed such that fluid can enter and leavechamber 104 through the inlet andoutlet channels beads 106 in place in thebead bed 104. - Referring to
FIGS. 2A and 2B , an array ofsample channels sample chamber 218, is formed in asubstrate 201. Thesample chambers 218 are functionally similar to thechamber 104 ofFIG. 1 , except that in the present embodiment,narrow channels 216 are used to retain thesurface augmentation particles 106, for example, beads. The beads are loaded into loading ports 202 (as indicated byarrow 237—only oneport 202 is labeled to avoid crowding the drawing, but the others are similarly configured). The beads are held back by thenarrow channels 216 and the fluid carrying the beads exits as shown by thearrow 239 out of anexit port 204. Using these structures, beads with different immobilized substances can be loaded in eachsample chamber 218. Once thesample chambers 218 are packed, theports device 200 can be used or stored and/or shipped. In other respects, thedevice 200 is similar to that described with reference toFIG. 1 . - In use, the sample, washes, and reagents (collectively indicated by arrow 235) are loaded through
sample inlet ports 212 and spent fluids recovered or disposed of through sample outlet port 206 (arrow 237). As described below,sample channels 210 convey a fluid train (the sample, washes, and reagents) serially through each of the sample chambers. Preferably, the fluid train is drawn through thedevice 200 using a vacuum pump regulated to maintain a pressure that provides desired shear rate which has been determined to remove particles that do not bind with the beads (more specifically, the active surface of the bead particles) and permit those particles (such as cells) that do bind to remain in thesample chambers 218. In certain embodiments, it will preferably be determined the range of shear rates that provide the desired discrimination behavior. -
FIG. 2B illustrate, as viewed from the top, asingle sample chamber 218 withbeads 240 packed within. Thesample channel 210 permits the train of sample fluid and reagents to pass through. Preferably, the sample line has a size that prevents the migration of substantial quantities ofbeads 240 from thesample chamber 218. In an embodiment, the sample channel width is selected to be slightly smaller than the coated beads. - As will be described below, sample fluid particles in sample fluid, such as CD4 cells (particles) in blood (sample fluid) flow into the sample chamber followed by a wash, followed by a fluid carrying free signal molecules, followed by a wash, followed by a fluid carrying a free signal amplifier molecule. In each case, a different shear rate may be desirable to ensure that only the reactive particles or molecules are left behind and such that the shear rate is not so high as to interfere with the ability of particles to attach ultimately to the beads or substances thereon. The shear rate may vary depending on the component of the assay, for example, when a wash is applied versus when a reagent is applied. Shear rate may vary for different reagents as well. Preferably, an automated device, as described below, is provided with a controller to vary the total vacuum to vary the shear rate accordingly. This may be synchronized to the stage of the assay by detecting a property of the fluid train (e.g. detecting air bubbles that isolate the fluids from each other), by time after start of the vacuum pump, by detecting momentary changes in the vacuum pressure caused by passage of different fluids, such as air, into the beds, or other means.
- Referring to
FIG. 3 ,beads 240 configured for capturing the target cells (such as by anti-target cell antibody) are packed in abed 218 in ananalyzer device 300. The device hastubing 312 withconnectors 356 that connect to samplefluid train 351 and avacuum pump 306. The sample fluid train may be held in along tube 307 which is sealed withrupturable seals 350. The rupturable seals may be configured to rupture upon application of a vacuum or by being pierced automatically by a sharp edge (not shown) when installed in a portable device. After the sample fluid train passes through thedevice 300, asignal detector 302 may detect light caused by a reaction, for example, chemiluminescence or fluorescence, In the latter case, a light source, such asphotodiode 304 may be provided. In a preferred embodiment, the number of cells captured in the sample chamber is the quantity of interest and preferably the system is configured such that the total amount of light captured by the detector indicates the number of cells according to a predetermined calibration curve stored in a portable controller and the cell count or other indication displayed automatically by the device. - The train of
fluid 310 includingsample fluid 320, such as whole blood conveyed through aninlet channel 312 to thebed 218. The sample fluid train may include further fluids, each separated from each other, as appropriate in view of their mutual activity, by air or gas bubbles 340. The fluid train may also includewashes signal molecules 324, developers and, fluids carryingsignal amplifiers 326, etc. For another example, the sample fluid train may include substance that causes chemoluminescence. - In a preferred embodiment, the target that reacts with the reactive substance on the beads is lymphocytes (for example CD4 cells) carried in the sample fluid, blood. In such embodiment, is followed by a wash and then a target cell antibody (the primary antibody). In the principal embodiment, this is a CD4 cell primary antibody; i.e., an antibody that recognizes a CD4 cell. Following that, a quantity of a detectable (labeled) secondary antibody that recognizes the CD4 cell antibody is conveyed through the inlet channel and binds or associates with the primary antibody. A developer may be conveyed as well to enhance or permit detection.
- As mentioned, to detect the quantity of target cells retained in the sample chambers, the device preferably measures the strength of an optical signal. Examples included fluorescence, label (e.g. silver) absorbance, and chemiluminescence. Techniques which are known in the prior art, may be employed. A small electronic (charge-coupled device; “CCD”) camera, microscope, or other suitable photodetector device can be employed with suitable optics and filtering to provide an indicator signal. The total magnitude of the light signal may be compared to a standard to quantify the count of cells.
- In an exemplary embodiment, the embodiments employ dimensions that are determined to permit the close packing in a single layer while permitting sufficient flow of sample fluid and reagents without clogging. The dimensions of the embodiment of
FIG. 1 may include 90 μm-diameter microposts 108 spaced apart a distance smaller than thebeads 108, for example, spaced 25 μm apart to trap them. The beads are 40 μm-diameter and the depth (dimension parallel to the axes of the microposts 108) of the channel defined by thebed 104 is 75 μm-tall channels. In an exemplary embodiment, thebed 104 is 2 mm by 2 mm. The void fraction of the packedbed 104 may be chosen such that cells clear the column after a few washes. - Referring to
FIG. 4A , a schematic of aportable analyzer 400 has apower source 404, for example, a solar cell or hand generator. A microprocessor based microcontroller (XTL) 402 controls the unit and drives a pump, (optionally, if used) a light source (e.g., laser diode) orother exciter 412,photodetector 410, and adisplay 408, preferably an LCD. Inputs from a user may be provided by suitable actuators such as membrane switches to allow a user to operate the device. Switches, 418 and 420 may be limited to power on and run functions to make the unit fully automated and simple to operate. A housing 422 is preferably provided to form a unitary portable device. - Referring to
FIG. 4B , a more detailed embodiment of aportable analyzer 450 has avacuum pump 462 to generate a vacuum for drawing sample and reagents through amicrofluidic chip 494 as discussed above. Apressure sensor 471 detects a pressure signal via apressure chamber 464 which smooths out pressure pulses, indicating the vacuum output of the vacuum pump. Anotherpressure sensor 470 detects a pressure signal via apressure chamber 468 which also smooths out pressure pulses, the latter signal indicating the regulated vacuum pressure determined by apressure regulator 466. The pressure signals are applied to amicrocontroller 488 as are signals fromuser control actuators 472, and photodetector signals from one ormore photodetectors 476 amplified by anamplifier 480. The signal from thephotodetectors 476 may are preferably sampled and converted to digital data and processed for analysis to permit results to be displayed on adisplay 482. Further output devices may include anindicator annunciator 484 and/or anindicator lamp 478. The latter may be used, for example, to indicate the completion of an analysis and the status of thedevice 450, respectively, for example. - Referring to
FIG. 4C , in a preferred embodiment, amicrofluidic chip 604 with reagent cache 602 (tube filled with reagent and having a sample port 603) is configured to be received in arecess 606 of ananalyzer 608 to form a configuration as described with reference toFIG. 4A or 4B. In the present embodiment, a swing-out front panel has asolar charger 614. Control buttons such membrane switches (not shown) may be provided on the housing. A circuit board (not shown) carrying anLCD display 615 may be carried on the front panel. The microfluidic channel “chip” 604 (and fluid train cache 602) may be provided in the form of a replaceable component which is used once for each measurement and discarded. In a following layer a circuit board carries a microcontroller and photodetector (or camera or other sensor) positioned to detect light from the bead bed. Batteries and a pump may be carried in a lower chassis. The entire structure shown can be packaged in a hinged device which may be opened to insert the microfluidic chip while permitting access for the drawing of a sample fluid (and any detection or development agents required). - In an exemplary embodiment, the laser diode may, for example, have a wavelength of 654 nm. The device may have an alignment slot, which is exposed when opened, to permit the proper location of the microfluidic chip. It may also have a Polydimethylsiloxane window to protect the detector and/or the light source. In an embodiment, the photodetector records changes in absorbance, for example due to opacity of a developing silver film. In another embodiment, the photodetector detects light emitted by captured sample material and labels, e.g., by fluorescence. Preferably, results are displayed digitally to minimize subjective interpretation by the user.
- To confirm the above configuration, a passive adsorption of antibodies onto beads was tested. The capture of 3T3 fibroblasts on the beads (coated with human fibronectin), and CD4 T-cells (using anti-CD4 antibodies) has been demonstrated by experiment. An ability to capture both fibroblasts and lymphocytes with this method (
FIG. 2A ), has been confirmed. The use of covalent chemistry has been investigated, using carboxylated beads and the carbodiimide coupling agent EDC. Beads coated with anti-CD4 successfully captured T-cells from whole blood of AIDS patients, by DIC (FIG. 2B ) and fluorescence microscopy (FIG. 2C ). Among commercially available antibodies, it was found that only a small number have strong affinity for CD4 and can be easily coated onto surfaces. Using this set of antibodies, we will finish a signal-to-background optimization by July 31 as scheduled. - To prepare glass beads, the following methodology was experimentally confirmed as suitable for use in the above embodiments. First, beads having a diameter of about 50 μm were subjected to 2N nitric acid wash for 1 hour (to clean the glass beads). Next, the beads were silanized with 10% APTES (an aminosilane) overnight at room temperature. The beads were washed with toluene and acetone, and dried in an oven at 60C for 2 hr. Then the beads were reacted with 2.5% glutaraldehyde (to crosslink terminal—NH2 on APTES with primary amines on proteins added later) for 1 hour at room temperature and subsequently washed with distilled water. The next step was to couple 10 μg/ml of protein G onto silanized glass surface (to orient anti-CD4+ antibody with F(ab) towards mobile phase, and to act as additional spacer). The next step was to wash 3 times with phosphate buffer saline solution and couple 10 μg/ml of mouse-anti-human CD4+ antibody onto protein-G coated glass surface. Specific binding of fluorescent antibodies was demonstrated, using bovine serum albumin (BSA) as a negative control to block binding of fluorescent secondary antibody markers (AF-488 goat anti-mouse antibodies).
- It has been experimentally determined that beads of a certain minimum size are preferred to reduce clogging by cell particles. In balancing the size against the reduction in surface, the preferred size range has been determined to be in the range of 50-100 and preferably about 75-80 μm diameter. An exemplary shear rate determined to provide reliable discrimination is 10-20 dyn/cm2.
Claims (17)
1-12. (canceled)
13. A portable blood component analysis device, comprising:
a microfluidic unit with a sample chamber;
the sample chamber having a surface augmentation features with biospecific surface configured to capture particles from blood; and
an analyzer component having a signal detector and a receiving slot configured to receive the microfluidic unit and align the sample chamber with the signal detector.
14. The device of claim 13 , wherein the surface augmentation features include a packed bead bed with glass beads.
15. The device of claim 13 , wherein the surface augmentation features include a packed bead bed with glass beads with a diameter between 50 and 100 μm and the first longitudinal channel contains a narrow portion with a minimum dimension of less than the diameter of the glass beads.
16. The device of claim 13 , further comprising a pump, a controller and a solar power source connected to power the pump and controller.
17. The device of claim 13 , wherein the microfluidic unit includes a tube containing at least one wash, and at least one air bubble, the tube being reversibly sealed at both ends and configured to connect with the second longitudinal channel.
18. The device of claim 13 , further comprising a pump, a controller and a solar power source connected to power the pump and controller, wherein the microfluidic unit includes a tube containing at least one wash, and at least one air bubble, the tube being reversibly sealed at both ends and configured to connect with the second longitudinal channel and wherein the controller is configured automatically to pump fluids from the tube through the sample chamber and through the second longitudinal channel.
19. The device of claim 13 , wherein the blood particles include CD4 cells.
20. The device of claim 13 , further comprising a battery.
21. The device of claim 13 , further comprising a controller and wherein the signal detector is a light intensity detector and the controller is configured to derive a cell count from a light intensity signal without imaging.
22. The device of claim 21 , wherein the controller is configured to derive the cell count from a calibration lookup table correlating cell count against total light intensity from the sample chamber.
23. The device of claim 18 , further comprising a display configured to output a cell count.
24. The device of claim 23 , further comprising a controller and wherein the signal detector is a light intensity detector and the controller is configured to derive a cell count from a light intensity signal without imaging.
25. The device of claim 24 , wherein the controller is configured to derive the cell count from a calibration lookup table correlating cell count against total light intensity from the sample chamber.
26. The device of claim 13 , further comprising a pump, a controller and a solar power source connected to power the pump and controller, wherein the microfluidic unit includes a tube containing at least one wash, and an a chemiluminescence activator, the tube being reversibly sealed at both ends and configured to connect with the second longitudinal channel and wherein the controller is configured automatically to pump fluids from the tube through the sample chamber and through the second longitudinal channel.
27. The device of claim 18 , wherein the pump is controlled to vary a pumping rate depending on a sample or reagent passing through the sample chamber.
28. The device claim 13 , wherein the analyzer includes a pump configured to generate a vacuum of at least 10 kPa.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/830,605 US20130203157A1 (en) | 2007-06-29 | 2013-03-14 | Microfluidic device for counting biological particles |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94734507P | 2007-06-29 | 2007-06-29 | |
US94738407P | 2007-06-29 | 2007-06-29 | |
PCT/US2008/068869 WO2009006456A1 (en) | 2007-06-29 | 2008-06-30 | Microfluidic device for counting biological particles |
US59417610A | 2010-03-08 | 2010-03-08 | |
US13/830,605 US20130203157A1 (en) | 2007-06-29 | 2013-03-14 | Microfluidic device for counting biological particles |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/068869 Division WO2009006456A1 (en) | 2007-06-29 | 2008-06-30 | Microfluidic device for counting biological particles |
US59417610A Division | 2007-06-29 | 2010-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130203157A1 true US20130203157A1 (en) | 2013-08-08 |
Family
ID=40226519
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/594,176 Expired - Fee Related US8431090B2 (en) | 2007-06-29 | 2008-06-30 | Microfluidic device for counting biological particles |
US13/830,605 Abandoned US20130203157A1 (en) | 2007-06-29 | 2013-03-14 | Microfluidic device for counting biological particles |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/594,176 Expired - Fee Related US8431090B2 (en) | 2007-06-29 | 2008-06-30 | Microfluidic device for counting biological particles |
Country Status (2)
Country | Link |
---|---|
US (2) | US8431090B2 (en) |
WO (1) | WO2009006456A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9366606B1 (en) | 2015-08-27 | 2016-06-14 | Ativa Medical Corporation | Fluid processing micro-feature devices and methods |
WO2017018977A1 (en) * | 2015-07-24 | 2017-02-02 | Hewlett-Packard Development Company, L.P. | Light guide for fluid testing cells |
EP3288766A4 (en) * | 2015-04-30 | 2018-12-05 | Hewlett-Packard Development Company, L.P. | Microfluidic optical fluid sensor |
EP3446090A4 (en) * | 2016-04-20 | 2020-03-11 | Hewlett-Packard Development Company, L.P. | Microfluidic pressure sensor |
US10612070B2 (en) | 2015-08-27 | 2020-04-07 | Ativa Medical Corporation | Fluid holding and dispensing micro-feature |
US11071982B2 (en) | 2015-08-27 | 2021-07-27 | Ativa Medical Corporation | Fluid holding and dispensing micro-feature |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8921121B2 (en) * | 2007-06-29 | 2014-12-30 | The Trustees Of Columbia University In The City Of New York | Methods, devices, and systems for chemiluminescence-based microfluidic cell counting |
AP3522A (en) * | 2010-11-09 | 2016-01-11 | Gen Hospital Corp | Counting particles using an electrical differential counter |
BR112016011566A2 (en) * | 2013-11-21 | 2017-08-08 | Schlumberger Technology Bv | TESTING APPARATUS FOR CHARACTERIZING PROPERTIES OF A FLUID, TEST METHOD FOR CHARACTERIZING PROPERTIES OF A FLUID, AND TEST METHOD FOR CHARACTERIZING PROPERTIES REGARDING THE CONDITION OF HYDRATE CLATHRATE FORMATION OF A FLUID INCLUDING A RESERVOIR FLUID COMPONENT |
CN103616426B (en) * | 2013-12-02 | 2016-05-11 | 中国科学院上海应用物理研究所 | A kind of micro-fluidic electrochemica biological sensor-based system and using method thereof of the integrated form for quick biochemical analysis |
WO2016025698A1 (en) * | 2014-08-13 | 2016-02-18 | The Trustees Of Columbia University In The City Of New York | Diagnostic devices, systems, and methods |
US10730044B2 (en) | 2015-10-01 | 2020-08-04 | The Regents Of The University Of Michigan | Assay plate and uses thereof |
CA3000389A1 (en) * | 2015-10-01 | 2017-04-06 | The Regents Of The University Of Michigan | Assay plate and uses thereof |
US9770717B1 (en) * | 2016-11-03 | 2017-09-26 | International Business Machines Corporation | Microfluidic chip with bead integration system |
US20180321233A1 (en) * | 2017-05-02 | 2018-11-08 | Sanguis LLC | System, Device and Method for Counting Desired Cells in a Body Fluid |
KR102185443B1 (en) * | 2018-04-25 | 2020-12-01 | (주)옵토레인 | Catridge for digital real-time pcr |
CN110068695B (en) * | 2019-04-19 | 2024-02-06 | 成都恩普生医疗科技有限公司 | Handheld portable automatic urine analysis instrument device |
CN113267602B (en) * | 2021-06-28 | 2023-10-03 | 福建师范大学 | Method and system for testing VOCs emission factors of single vehicle evaporation emission operation loss |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6767706B2 (en) * | 2000-06-05 | 2004-07-27 | California Institute Of Technology | Integrated active flux microfluidic devices and methods |
US20050136548A1 (en) * | 2000-01-31 | 2005-06-23 | Board Of Regents, The University Of Texas System | System and method for the analysis of bodily fluids |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4164597A (en) | 1996-08-26 | 1998-03-19 | Princeton University | Reversibly sealable microstructure sorting devices |
DE69709377T2 (en) | 1996-09-04 | 2002-08-14 | Scandinavian Micro Biodevices | MICROFLOWING SYSTEM FOR PARTICLE ANALYSIS AND SEPARATION |
US6632619B1 (en) | 1997-05-16 | 2003-10-14 | The Governors Of The University Of Alberta | Microfluidic system and methods of use |
US6942771B1 (en) | 1999-04-21 | 2005-09-13 | Clinical Micro Sensors, Inc. | Microfluidic systems in the electrochemical detection of target analytes |
AU2001232805A1 (en) | 2000-01-12 | 2001-07-24 | Ut-Battelle, Llc | A microfluidic device and method for focusing, segmenting, and dispensing of a fluid stream |
US8071051B2 (en) | 2004-05-14 | 2011-12-06 | Honeywell International Inc. | Portable sample analyzer cartridge |
US7026131B2 (en) | 2000-11-17 | 2006-04-11 | Nagaoka & Co., Ltd. | Methods and apparatus for blood typing with optical bio-discs |
AU2002352735A1 (en) | 2001-11-20 | 2003-06-10 | Burstein Technologies, Inc. | Optical bio-discs and microfluidic devices for analysis of cells |
WO2003060486A1 (en) | 2002-01-10 | 2003-07-24 | Board Of Regents, The University Of Texas System | Flow sorting system and methods regarding same |
US7312085B2 (en) | 2002-04-01 | 2007-12-25 | Fluidigm Corporation | Microfluidic particle-analysis systems |
US8168139B2 (en) | 2002-06-24 | 2012-05-01 | Fluidigm Corporation | Recirculating fluidic network and methods for using the same |
US6936167B2 (en) | 2002-10-31 | 2005-08-30 | Nanostream, Inc. | System and method for performing multiple parallel chromatographic separations |
US7736889B2 (en) | 2003-06-10 | 2010-06-15 | The United States Of America As Represented By The Secretary Of The Navy | Fluidic force discrimination |
WO2005066613A1 (en) | 2003-12-31 | 2005-07-21 | President And Fellows Of Harvard College | Assay device and method |
US7598091B2 (en) | 2006-04-04 | 2009-10-06 | Micropoint Bioscience, Inc. | Micromachined diagnostic device with controlled flow of fluid and reaction |
US7807454B2 (en) | 2006-10-18 | 2010-10-05 | The Regents Of The University Of California | Microfluidic magnetophoretic device and methods for using the same |
US8008032B2 (en) | 2008-02-25 | 2011-08-30 | Cellective Dx Corporation | Tagged ligands for enrichment of rare analytes from a mixed sample |
-
2008
- 2008-06-30 US US12/594,176 patent/US8431090B2/en not_active Expired - Fee Related
- 2008-06-30 WO PCT/US2008/068869 patent/WO2009006456A1/en active Application Filing
-
2013
- 2013-03-14 US US13/830,605 patent/US20130203157A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050136548A1 (en) * | 2000-01-31 | 2005-06-23 | Board Of Regents, The University Of Texas System | System and method for the analysis of bodily fluids |
US6767706B2 (en) * | 2000-06-05 | 2004-07-27 | California Institute Of Technology | Integrated active flux microfluidic devices and methods |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3288766A4 (en) * | 2015-04-30 | 2018-12-05 | Hewlett-Packard Development Company, L.P. | Microfluidic optical fluid sensor |
US10365226B2 (en) | 2015-04-30 | 2019-07-30 | Hewlett-Packard Development Company, L.P. | Microfluidic optical fluid sensor |
WO2017018977A1 (en) * | 2015-07-24 | 2017-02-02 | Hewlett-Packard Development Company, L.P. | Light guide for fluid testing cells |
US10401280B2 (en) * | 2015-07-24 | 2019-09-03 | Hewett-Packard Development Company, L.P. | Light guide for fluid testing cells |
US9366606B1 (en) | 2015-08-27 | 2016-06-14 | Ativa Medical Corporation | Fluid processing micro-feature devices and methods |
US10612070B2 (en) | 2015-08-27 | 2020-04-07 | Ativa Medical Corporation | Fluid holding and dispensing micro-feature |
US11071982B2 (en) | 2015-08-27 | 2021-07-27 | Ativa Medical Corporation | Fluid holding and dispensing micro-feature |
EP3446090A4 (en) * | 2016-04-20 | 2020-03-11 | Hewlett-Packard Development Company, L.P. | Microfluidic pressure sensor |
US11441960B2 (en) | 2016-04-20 | 2022-09-13 | Hewlett-Packard Development Company, L.P. | Microfluidic pressure sensor |
Also Published As
Publication number | Publication date |
---|---|
US8431090B2 (en) | 2013-04-30 |
WO2009006456A1 (en) | 2009-01-08 |
US20110243790A1 (en) | 2011-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8431090B2 (en) | Microfluidic device for counting biological particles | |
US11458473B2 (en) | Systems and devices for analysis of samples | |
US20180100872A1 (en) | Chip-based flow cytometer type systems for analyzing fluorescently tagged particles | |
JP6349327B2 (en) | System and method for determining a chemical state | |
CN101091115B (en) | Analytic system | |
CN1985168B (en) | Portable sample analyzer with removable cartridge | |
US20060257941A1 (en) | Integration of fluids and reagents into self-contained cartridges containing particle and membrane sensor elements | |
US20060257992A1 (en) | Integration of fluids and reagents into self-contained cartridges containing sensor elements and reagent delivery systems | |
US20130236914A1 (en) | Devices and methods for analysis of samples with depletion of analyte content | |
CA2557563A1 (en) | Particle on membrane assay system | |
EP2067035A2 (en) | Surface mapping by optical manipulation of particles in relation to a functionalized surface | |
CN101573618A (en) | Surface mapping by optical manipulation of particles in relation to a functionalized surface | |
WO2008156491A2 (en) | Devices and methods for analysis of samples with depletion of analyte content | |
EP2307871B1 (en) | Fluid providing apparatus | |
US20200147611A1 (en) | Microchip for analyzing fluids | |
US20220097063A1 (en) | Apparatus for Automatic Sampling of Biological Species Employing Disk Microfluidics System | |
AU2015202055B2 (en) | Systems and devices for analysis of samples | |
Neikirk et al. | Method and system for the analysis of saliva using a sensor array |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHEUNG POH, YUK KEE;SIA, SAMUEL K;CHIN, CURTIS D;AND OTHERS;SIGNING DATES FROM 20130422 TO 20131109;REEL/FRAME:031903/0963 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |